8-K filed Feb 26, 2026 at 07:57 ET
PROCEPT BioRobotics disclosed its 2026 Analyst Day presentation, highlighting strong financial guidance with 2026 revenue projected between $390M and $410M (27-33% growth), improved gross margins targeting 65% in 2026 and 68-70% in 2027, and a clear path to profitability with adjusted EBITDA expected to turn positive in Q4 2026 and reach $25-30M gain in 2027. The company emphasized commercial execution, HYDROS system adoption, and expansion into prostate cancer treatment.